Business
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2
About this update from Pharvaris N.v.
[{"type":"text","content":"ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows: Title: Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic RatPresenter: Jolanta Skarbaliene, Ph.D.Format: Oral Presentation, Session IIDate, time: Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT) Title: Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoLPresenter: Markus Magerl, M.D.Format: Oral Presentation, Session VIIDate, time: Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT) Title: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE ProphylaxisPresenter: Marc A. Riedl, M.D., M.S.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT) Title: Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension ResultsPresenter: Emel Aygören-Pürsün, M.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT) Title: Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 ResultsPresenter: Emel Aygören-Pürsün, M.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT) Title: Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched AnalysisPresenter: Marc A. Riedl, M.D., M.S.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT) Title: Clinical Trials Conformity with AURORA COS: a systematic literature reviewPresenter: Remy Petersen, M.D., Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT) Title: Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibantPresenter: Nieves Crespo, Ph.D.Format: Poster PresentationDate, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT) Title: The bradykinin challenge model translates across rat, monkey and humanPresenter: Juan Bravo, Ph.D.Format: Poster PresentationDat...